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Abstract
Alzheimer’s disease (AD) is the most common cause of dementia in the elderly, affecting
over 10% population over the age of 65 years. Clinically, AD is described by the symptom
set of short term memory loss and cognitive decline, changes in mentation and behavior,
and eventually long-term memory deficit as the disease progresses. On imaging studies,
significant atrophy with subsequent increase in ventricular volume have been observed.
Pathology on post-mortem brain specimens demonstrates the classic findings of increased
beta amyloid (Aβ) deposition and the presence of neurofibrillary tangles (NFTs) within
affected neurons. Neuroinflammation, dysregulation of blood-brain barrier transport and
clearance, deposition of Aβ in cerebral blood vessels, vascular risk factors such as athero-
sclerosis and diabetes, and the presence of the apolipoprotein E4 allele have all been iden-
tified as playing possible roles in AD pathogenesis. Recent research has demonstrated the
importance of the glymphatic system in the clearance of Aβ from the brain via the perivascu-
lar space surrounding cerebral blood vessels. Given the variety of hypotheses that have
been proposed for AD pathogenesis, an interconnected, multilayer model offers a unique
opportunity to combine these ideas into a single unifying model. Results of this model dem-
onstrate the importance of vessel stiffness and heart rate in maintaining adequate clearance
of Aβ from the brain.
Introduction
Alzheimer’s disease (AD) is a multi-faceted, progressive neurodegenerative disease. It is the
most common cause of dementia in the elderly, affecting nearly 1 in 8 individuals over the age
of 65 in the United States [1]. AD has been clinically described by the symptoms of short-term
memory deficits, cognitive decline and eventual long-term memory deficit. These deficits lead
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to a decreased quality of life, often eventually requiring assistance with activities of daily living
(ADLs) in a long term care setting [1–2]. There is a tremendous burden for the cost of care
even though no preventative or curative treatments are available. Given the increasing number
of the elderly affected by AD and the lack of any viable treatment options, there is a pressing
need to develop a better understanding of the disease process as well as effective treatment
modalities.
Beta amyloid levels within the brain, particularly the oligomeric form, are linked to the loss
of neurons, stimulation of neuroinflammation, abnormal mitochondrial function and increase
in tau levels [3–10]. Decreased clearance of Aβ from the brain via the glymphatic system and
the low-density lipoprotein-related receptor 1 (LRP-1) have been implicated in the pathogene-
sis of AD, and have been known to occur in normal aging as well [11–12]. The glymphatic sys-
tem (located in the perivascular space) is believed to drain approximately 60% of the brain Aβ
to cervical lymph nodes using convective flow generated by arterial pulsations [13–16].
Increased vessel stiffness causing decreased flow of brain interstitial fluid (ISF) is believed to
lead to decreased Aβ clearance with aging [14, 17]. As Aβ concentration builds within the peri-
vascular space, deposition occurs slowly, eventually leading to the breakdown of the blood-
brain barrier secondary to degeneration of smooth muscle cells and brain endothelial cells [14].
Beta amyloid deposition in blood vessels has also been shown to inhibit angiogenesis, impair
vascular tone and decrease local cerebral perfusion [14, 18]. Clearance of Aβ by LRP-1 has also
been shown to decrease by nearly 55% during aging and is believed to be secondary to loss of
brain endothelial cells [19].
Given the complex nature of cellular and molecular interactions, mathematical modeling
offers a unique opportunity to further understand the pathogenesis of AD. Several other math-
ematical models of AD have been proposed, with the majority focusing on Aβ fibril nucleation
and growth of Aβ plaques [20–21]. Puri and Li developed a network model to study the inter-
actions between neurons, astrocytes and microglia, while Luca et al presented a model on
microglia chemotaxis towards Aβ [22–23]. However, there has been no model developed to
study the transport of Aβ from generation at the neuron to clearance at the blood-brain barrier
or via the glymphatic (eg. perivascular) pathway.
The model presented in this paper studies how Aβ levels change within the brain paren-
chyma and vasculature during normal aging while incorporating the role of the glymphatic sys-
tem. Conservation of mass equations are used to model Aβ levels. Neurons, microglia and
brain endothelial cells interacted dynamically and responded to both parameters determined
by aging process, as well as with the Aβ levels. The role of increased vessel stiffness secondary
to aging, prolonged hypertension and cerebrovasculature deposition of Aβ, as well as alter-
ations in heart rate, were also studied given the correlation between cardiovascular risk factors
and AD. The results of this model demonstrate the importance of maintaining healthy cardio-
vascular function and offer insight into possible preventive or treatment options in the future.
Methods
Model Assumptions
This model describes the flow of several key chemical species within a 1 mm3 volume of CA1
hippocampal tissue (volume of CA1 in healthy patients is approximately 640 mm3, total hippo-
campal volume in healthy patients is around 2100 mm3)[24]. The system is divided into three
compartments: the blood within the nearby cerebral capillaries; the blood-brain barrier (BBB)
and associated perivascular space; and the brain parenchyma, respectively. Capillaries are
aligned in parallel with a separation distance of 40 μm [25] and assumed to be have a linear seg-
ment length of 1 mm. Neurons and microglia reside within the brain parenchyma between the
Modeling Alzheimer's Disease Pathogenesis
PLOS ONE | DOI:10.1371/journal.pone.0139574 October 8, 2015 2 / 20
Competing Interests: The authors have declared
that no competing interests exist.
capillaries and are assumed to have a uniform density. Fig 1 demonstrates the overall layout of
the system being modeled.
Each compartment is assumed to be well-mixed with uniform spatial distribution. From
recent studies, it has been demonstrated that Aβ is quickly transported from the site of genera-
tion via a combination of diffusion (diffusion coefficient, D, range of 1.6–6.23x10−7cm2/s for
monomers to 4x10−9 cm2/s for oligomers) and convective flow via the bulk brain ISF (0.1–
0.3μm/min/g brain tissue [26–28]. Spatial variation of chemical species such as Aβ does occur,
however, the time course of this variation given the relatively small intercapillary distance
(40 μm [25]) is negligible compared to the time scale used in the simulation.
Beta amyloid is generated by neurons within the brain parenchyma, rapidly mix with brain
ISF, and Aβ is transported towards the blood-brain barrier for further transport or clearance
[15, 29]. Brain ISF flows along the basement membrane of capillaries and arterioles, to the
walls of cortical and leptomeningeal arteries, to the base of the skull before exiting the brain for
Fig 1. Three compartment model used for modeling. The brain was divided into the brain parenchyma,
containing the neurons (N) and astrocytes (A); the perivascular space (PVS, blue strip) in the area between
the astrocytic foot processes and the brain endothelial cells; and the cerebral blood vessels (B). Interstitial
(ISF) flow is unidirectional and laminar in the regions lined by capillaries; its rate is dependent on heart rate
(eg. the rate of arterial pulsations) as well as the stiffness of the vessels, which is a function of the presence of
atherosclerosis, cerebral amyloid angiopathy (deposition of beta amyloid within the brain vessels) and
stiffening secondary to prolonged elevations in systemic blood pressure.
doi:10.1371/journal.pone.0139574.g001
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the cervical lymph nodes [14]. It is not known whether significant levels of transported sub-
stances build-up at the cervical lymph nodes. ISF flow is assumed to be unidirectional, well-
mixed, and originating from the pulsations of arterial vessels in response to the cardiac cycle
(Fig 2). There is some debate in the literature as to whether glymphatic flow is in the same or
opposite direction as cerebral blood flow; this model assumes that flow is in the same direction
[13, 16]. ISF flow rate is dependent on the heart rate, the ability of the vessel wall to transmit
pulsations (eg. the compliance of the arterial wall). Arterial wall compliance can be estimated
by wall stiffness (S), which increases with age, hyalinosis secondary to prolonged hypertension,
atherosclerosis and vasculitis [14–15]. It is important to note that although brain ISF is gener-
ated by brain endothelial cells at the capillary and other vessels, only the arteries and arterioles
possess the smooth muscle cells necessary to produce the pulsations to cause ISF flow [30–31].
Once transported to the blood, molecules are rapidly cleared away at a rate of once per sec-
ond (assuming a heart rate of 60 beats per minute). The blood has also been assumed to be well-
mixed and serves as a relative sink for Aβ. Although viscosity of blood can change during aging
and disease (eg. diabetes, dehydration), we have not modeled these changes here and assumed
that the viscosity and physical properties of blood remain constant throughout the simulation.
Model Derivation
Cell numbers. The volume of the hippocampus has been estimated by both neuropathol-
ogy and magnetic resonance imaging (MRI) in healthy controls, as well as in patients with mild
cognitive impairment (MCI) and AD [24, 32]. Follow-up MRI imaging demonstrated a signifi-
cant increase in the rate of volume loss in patients with AD or MCI of nearly 5 and 3 times,
respectively, the rate of volume loss in healthy controls (table 1) [24]. The total neurons loss in
the CA1 region during an average course of AD (15–20 years) has been estimated at 50–60%,
much faster than that observed with normal loss during aging (1%, or a 50% loss over 69
years), and demonstrating the impact that the faster loss rate has on the AD-afflicted brain.
Fig 2. Flow of brain interstitial fluid in response to pulsations of cerebral arteries and arterioles. Interstitial fluid is generated at the brain endothelium
by an unclear process [30] and surrounds neurons, microglia astrocytes and other cells located within the brain parenchyma, bringing nutrition to the cells
and removing wastes. Although its chemical composition is similar to cerebrospinal fluid (CSF), the two fluids serve separate purposes. CSF gives the brain
buoyancy and buffers against forces applied to the head; CSF is generated by ependymal cells within the choroid plexus [30]. Brain ISF transports waste
from the brain parenchyma via a combination of convection and diffusion towards the perivascular space. At the perivascular space, molecules such as Aβ,
are either transported by receptors at the blood-brain barrier, or are transported along the glymphatic pathway. A small percentage of molecules transported
in the perivascular space are transported into the cerebrospinal fluid at the arachnoid granulations and are cleared from the brain via CSF drainage
pathways. The majority (~60%) of Aβ is transported along the glymphatic system to the cervical lymph nodes [13].
doi:10.1371/journal.pone.0139574.g002
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The number of neurons located in the CA1 region of the hippocampus was estimated from
the works of Harding and Zarow [33–34]. Zarow et al described the changes in neuron number
with respect to the Braak staging, and found that patients with a Braak stage of 0 (essentially
healthy, no presence of neurofibrillary tangles) had approximately 3.25x106 CA1 neurons,
while those with a Braak score of 6 (severe AD pathology) had only 1.5x106 CA1 neurons [34].
The maximum number of CA1 neurons reported [33] was 6.14x106. Total volume of the CA1
was estimated to be 641 ± 153 mm3 in healthy normal patients, decreasing to 377.5 ± 132 mm3
in patients with AD [32]. From this, we derived the density of neurons in the CA1 region to be
5275/mm3 (4050-6500/mm3) in healthy controls and 4500/mm3 (range 3000–6000) in AD [17,
35–37]. The change in neuron number over time can thus be described by:
dN
dt
¼ ð1 ðk1 þ dÞÞNðtÞ ð1Þ
where d is the natural rate of neuron loss in the healthy control, k1 is the additional neuron loss
due to increased beta amyloid levels seen in AD or the presence of the ApoE4 allele, and N is
the number of neurons within the control volume.
The density of microglia within several brain regions has been estimated via neuropathol-
ogy. Tetreault et al found that the average density microglial density in the neocortex is approx-
imately 5951 microglia/mm3 [38]. The total number of microglia has been found to vary
depending on gender, with women only having 1.9x109 and men having 2x109 microglia [39].
Calculating the microglial density from these values, also noting the slightly lower average
brain volume for women, we find that microglial density in women is about 3080 microglia/
mm3 and 3420 microglia/mm3 in men [39]. The number of microglia were also found to
decrease over time secondary to dystrophy at a conversion rate of about 80% by 65 years old
[40]. Given this range, the microglia density was set at 4500 microglia/mm3 with a conversion
to dystrophy rate of 7.3x10−5/day. The equation for microglia number is given by:
dM
dt
¼ ð1 k12ÞMðtÞ ð2Þ
where k12 is the conversion to dystrophy rate and M is the number of microglia within the
modeled volume.
Brain endothelial cells (ECs) line cerebral capillaries and work with astrocytes to form the
blood-brain barrier (BBB). Between the astrocyte foot processes and the endothelial cells is the
perivascular space (PVS), a narrow space (50–100 nm) composed of the basement membrane
that allows movement of brain ISF from the capillaries towards the arteries [12, 14, 41]. Endo-
thelial cells in low-flow vessels (such as capillaries) have been found to take on a hexagonal or
polygonal shape, with only a single endothelial cell wrapping end-to-end to form the capillary
Table 1. Volume of the human hippocampus as determined by MRI.
Patient Healthy MCI AD
Baseline volume (mm3) 2133 (25) 1846 (23) 1631 (34)
Rate of loss/year (mm3/yr) -17.3 (10.5) -47.5 (6.5) -72.0 (9)
% loss/year (%/yr) -0.8 (0.5) -2.6 (0.3) -4.4 (0.6)
MCI, mild cognitive impairment; AD, Alzheimer’s disease. Volume loss was approximately 1% in healthy
controls, 2.5% in MCI and 4.5% in AD patients. The rate of loss in AD patients was noted to increase by
1.4%/year (total rate of 5.8%.year) in patients with AD carrying the ApoE4 allele. Values are given as the
mean with standard deviation in parentheses.
doi:10.1371/journal.pone.0139574.t001
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wall. Given that the average capillary wall is approximately 8 μm in diameter, the circumfer-
ence of the “wrapped” brain capillary endothelial cells can be estimated as 25 μm. Polygonal
endothelial cells with this length have been estimated to be between 10–20 μm in width [42–
44]. For modeling purposes, we have assumed the final dimensions to be 25 by 20 μm, or
approximately 5 endothelial cells per 100 μm capillary length.
Brain ECs have a natural replacement rate of 0.1% per day [45–46], increasing to 1–10% per
day if ECs are being exposed to high blood pressure or turbulent flow [45]. During mitosis and
EC replacement, some cells are abnormally created leading to EC senescence. This is a process
where endothelial cells divide to replace damaged cells and maintain the capillary wall, how-
ever, there is local breakdown of the BBB as tight junctions fail to form correctly [47–48].
Denuded spots and disruption of capillary laminar flow have been hypothesized to occur with
senescence [47–48]. Approximately 3–7% of ECs are senescent in a 65 year old exposed to nor-
mal stressors; this rate increases to 41–93% senescence when ECs are exposed to only twice the
level of stressors [47]. Assuming the higher rates of senescence, this translates to a senescence
rate of 0.1% per year under normal conditions and 1.4% per year under increased stressors.
The equation for the number of brain ECs is then given by:
dEC
dt
¼ ð1 k2ÞECðtÞ ð3Þ
where k2 is the rate of ECs entering senescence and EC is the number of brain endothelial cells
lining the capillaries in the model volume.
Chemical Species
Beta amyloid. Beta amyloid is generated by neurons after the sequential processing of the
0amyloid precursor protein (APP) by β- and γ-secretase and is found deposited in both the brain
parenchyma as well as the cerebral vasculature. The generation rate has been estimated as 3x10−4
pg per neuron per day, or the equivalent order of 104 molecules per neuron per day [2]. The ratio
of Aβ42 to Aβ40 generation has been found to be approximately 1:5 [49]. From this data, the gen-
eration rate for Aβ40 was set at 1.6x10
4 and Aβ42 was set at 3x10
3. The average concentration of
Aβ within brain parenchyma has been estimated using both mice and human brains. Marklund
et al used microdialysis probes placed into the brains of patients following traumatic brain injury
and noted average Aβ40 levels of 436 pg/mL (range 281.3–971.3 pg/mL) and Aβ42 levels of 60 pg/
mL (range 46–90 pg/mL; values measured in patients with focal brain injury away from the site
of injury) [5]. Studies using human brain homogenates have shown similar results (73 pg/mL for
Aβ42 and 440 pg/mL for Aβ40) [35]. Using this range, the initial concentrations for Aβ40 and
Aβ42 are 450 pg/mL and 70 pg/mL, respectively. The general conservation of mass equation can
be used to define the change of Aβ within the brain parenchyma as:
@C
@t
¼ rN þ R; where N ¼ DrC þ vC ð4Þ
where N is the molar ﬂux, D is the diffusion coefﬁcient of Aβ, C is the volume concentration of
Aβ, v is the fully developed velocity of the ISF, and R is the volumetric rate of chemical reactions
taking place within the control volume given by the rate of Aβ transport by LRP-1 at the BBB.
Given the assumptions that ﬂow is unidirectional, fully developed and laminar (given the small
length scales modeled) in the region modeled, this equation can be further simpliﬁed as:
dC
dt
¼ v dC
dx
 R ð5Þ
Modeling Alzheimer's Disease Pathogenesis
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where R represents the generation of Aβ (k3, k4), the rate of uptake by microglia (k5), and the
rate of deposition within the brain parenchyma (k7a). Degradation of Aβ by extracellular
enzymes such as neprilysn have been shown to be negligible in vivo [19, 50]. The ﬁnal equation
for Aβ within the brain parenchyma is given by:
dC1
dt
¼ v dC
dx
þ k3k4NðtÞ  k5MðtÞ  k7aC1ðtÞ ð6Þ
The concentration of Aβ in the perivascular space (C2 for Aβ40 and C5 for Aβ42) is derived
using a similar simplification of Eq (5) where the concentration differential is still between the
brain ISF and the perivascular space. The velocity of the bulk ISF flow was assumed to be
approximately double that in an older person and was accounted for in the model. The reaction
term is described by the transport rate of Aβ by LRP-1 at the BBB (k6) and the rate of deposi-
tion in the perivascular space (k7):
dC2
dt
¼ v dC
dx
 k6
LRPðtÞ
LRP0
 
C2ðtÞ  k7C2ðtÞ ð7Þ
where LRP0 is the initial concentration of LRP-1 receptors on the brain endothelial cells. A
similar equation is used to calculate the Aβ42 concentration in the perivascular space (C4) with
rate constant k7 replaced with k9a. A term for ApoE was not directly included in Eq (7) given
the recent evidence that ApoE may not play a signiﬁcant role in Aβ clearance by LRP-1 and
may actually, in fact, be a competitive inhibitor of Aβ transport since both bind to the LRP-1
receptor [15, 51–52]. Further evidence for this possibility was shown by Shibata et al who
noted that there was minimal difference in transport rates in wild-type mice versus ApoE
knockout mice [19]. Bell et al conﬁrmed this in their studies of Aβ clearance by LRP-1 and
demonstrated that the clearance rate of Aβ bound to ApoE was only about 10% the transport
rate of Aβ alone [53]. There is an effect of the ApoE allele, however, on the amount of Aβ trans-
ported by LRP-1, as it is believed that ApoE4 may actually bind to LRP-1 longer, thus, increas-
ing potential inhibition of the LRP-1 receptor and slowing clearance of Aβ from the brain [52].
Bachmeier et al demonstrated that clearance of LRP-1 decreased by approximately 2.5 times
when the ApoE4 allele was compared to the ApoE3 allele [54].
Review of the literature demonstrated a wide range of transport rates for LRP-1, ranging
from 0.015/min to 0.03/min of the fraction of Aβ40 injected [19, 55–56]. Bell et al measured the
transport rate constant in pmol/min/gram of ISF and found the rate to be 0.211 for Aβ40 and
0.111 for Aβ42 [53]. Using the conversion for density of brain tissue of 0.99g/cm
3 [57], this
would be equivalent to 12x107 molecules/min/mm3 brain, which is more than a magnitude of
order elevated beyond the steady state concentration that has been measured in vivo. Given the
disparity and incongruency in the LRP-1 rate constants in the literature, we used the assump-
tion that 40% of Aβ is cleared by LRP, while the remaining Aβ is cleared by the perivascular
pathway or is deposited [11]. This rate of clearance decreased with aging as the density of LRP-
1 receptors decreased in response to declining numbers of functioning brain endothelial cells.
Deposition of Aβ within the brain parenchyma (C9) occurred at a constant rate over time
dependent on the concentration of Aβ:
dC9
dt
¼ k7aC1ðtÞ for Aβ40 ;
dC10
dt
¼ k9C4ðtÞ for Aβ42 ð8Þ
where C1 is the concentration of Aβ40 within the brain parenchyma and C4 is the concentration
of Aβ42 in brain ISF. Deposition of Aβ within the cerebral vessel similarly occurred at a
Modeling Alzheimer's Disease Pathogenesis
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constant rate related to the Aβ concentration within the perivascular space:
dC3
dt
¼ k7C2ðtÞ for Aβ40 ;
dC6
dt
¼ k9C5ðtÞ for Aβ42 ð9Þ
LRP density. The density of the LRP-1 receptor on brain endothelial cells was determined
experimentally by Hvidberg et al to be approximately 31 fmol/mm3 [58]. In the model, a 1mm2
area would contain an array of 21 by 21 capillaries. The depth of this array would contain 50
brain ECs, thus, the total density of LRP-1 receptors in the model volume (1mm3) would be
9.3x1011. During normal aging, the total number of LRP-1 receptors in a given volume decreases
by about 55% [19]. Assuming that this loss occurs secondary to the loss of brain endothelial
cells with, the rate of LRP-1 loss (k10) is equal to the rate of loss of endothelial cells (k2):
dLRP
dt
¼ ð1 k10ÞLRPðtÞ ð10Þ
The values for each of the rate constants are given in Table 2.
Simulation conditions. The model was simulated using Matlab. Initial conditions
assumed that the model described a 30 year old and was run for a total of 50 years. The time-
step used was a single day. Thus, a total of 18,250 data points were determined. Sensitivity anal-
ysis was completed for rate constants that were estimated (initial concentration in perivascular
space, increased generation of Aβ when a stimulus is present).
Table 2. Rate constants and initial conditions used in modeling.
Variable Represents Units Value Reference
N # of neurons #/volume 5275 (4050–6500) 5, 7–8, 11, 20
M # of microglia #/volume 4500 (3000–6000) 23–24
EC # of brain ECs #/length 5 per 100μm (capillaries) 9, 12, 18, 26
C1/C4 Initial Aβ conc. in brain ISF pg/ml Aβ40: 450 (240–770) Aβ42: 70 (40–100) 5, 8, 17
C2/C5 Initial Aβ conc. in PVS mass/vol 10% C1i/C4i Model assumption
C3/C6 Concentration of Aβ in vessels mass/vol 0 (initially) Model assumption
C9/C10 Conc. of Aβ deposited in brain mass/vol 0 (initially) Model assumption
k1 Loss of neurons when stimulated %/time 3.4%/yr 7–8
d Natural rate of neuron loss %/time 1%/yr 7–8
k2 Loss of ECs %/time 0.1%/yr (no stim)
1.7%/yr (stim)
16, 19
k3/k8 Aβ40/42 generation rate #/neuron/ time Aβ40: 16000
Aβ42: 3000
15
k4 Stimulated Aβ generation rate %/time 1.5 Estimate
k5/k11 Microglia uptake rate #/microglia/ time Aβ40: 1400
Aβ42: 200
Estimated from 3–4
k6 Aβ transport rate constant for LRP 1/time ApoE2/3: 0.4
ApoE4: 0.12
2, 21
k7/k9a Aβ deposition rate in vessels fraction/day Aβ40: 0.004
Aβ42: 0.002
6, 21
k9/k7a Aβ deposition rate in brain fraction/day Aβ40: 0.001
Aβ42: 0.001
6, 21
Values were derived from experimental studies or estimated given available data. We assumed that there was no Aβ deposited in the brain parenchyma
or cerebral vessels at the beginning of the simulation.
doi:10.1371/journal.pone.0139574.t002
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Results
The objective for the model was to study the role that aging has on the clearance of Aβ via the
perivascular pathway and transport at the blood-brain barrier by LRP-1. Normal aging causes
a slow, steady decrease in the number of neurons in the brain with minor accumulation of Aβ
within brain parenchyma and cerebral vessels in the majority of individuals. This was demon-
strated clearly in our simulation of normal aging (Fig 3).
Heart rate leading to arterial pulsations is important for maintaining the clearance provided
by the perivascular glymphatic pathway. During aging, it is common for patients to develop
heart rate abnormalities, either too slow of a heart rate (bradycardia), too fast (tachycardia) or
an abnormal rate (atrial fibrillation). We hypothesized prior to running simulations that having
bradycardia would lead to a decreased Aβ clearance rate and thus, lead to an elevation in Aβ
deposition. Conversely, we postulated that an elevated heart rate (for example, from exercising
daily) would help to increase the clearance rate and thus decrease the amount of Aβ available for
deposition. This was in fact what was seen (Fig 4), with the amount of Aβ deposition in the brain
parenchyma increasing by about 20% while deposition within cerebral vessels was minimal
(about 5%). Additionally, an elevated heart provided slightly better survival for neuron number.
The stiffness of blood vessels is known to increase over time with aging. Vessel stiffness can
also increase significantly in diseases such as atherosclerosis and cerebral amyloid angiopathy,
two diseases that increase the risk of transitioning to AD in older age. Increasing the stiffness
of vessels by a factor of 2 over the course of the simulation via an exponential rise, surprisingly,
led to a significant increase in Aβ deposition within brain parenchyma with Aβ40 increasing
nearly 100x and Aβ42 increasing greater than a factor of 10
3, a level often seen in the brains of
those with AD (Fig 5). Beta amyloid deposited within cerebral vessels actually decreased, most
likely secondary to less Aβ reaching the perivascular space by convection alone. There was also
increased neuronal cell death given the high Aβ levels, with neuron number decreasing to
about ½ of the normal age-matched simulation.
The ApoE4 allele is a well-known risk factor for having late-onset AD and is found in 65–
80% of all AD cases [59]. Approximately 15–20% of the population is a carrier for ApoE4
(either homozygote or heterozygote), and thus, have an increased risk of AD. The other two
alleles (ApoE2 and ApoE3) are not known to contribute to AD risk and are carried by 5–10%
and 65–70% of the population, respectively [59]. It is believed that the ApoE4 allele may con-
tribute to elevated Aβ levels by either competitively inhibiting Aβ binding to LRP-1, or by caus-
ing inefficient binding of the ApoEAβ complex to LRP-1 [51, 59]. Decreasing the transport
rate of Aβ by LRP-1 by 2.5 times over the course of the simulation led to approximately a two-
fold increase in Aβ40 deposition and a 67% increase in Aβ42 deposition in cerebral vessels.
There was no additional accumulation of Aβ within the brain parenchyma or changes in cell
number (Fig 6).
The final simulations studied the effect of multiple risk factors on changes in Aβ levels. Of
the risk factors studied, heart rate and vessel stiffness were the two that could be somewhat
modifiable. In Fig 7a, we show that the combination of the ApoE4 allele with bradycardia led
to an increase in all Aβ parameters measured, with the most significant increase in Aβ40 in
cerebral vessels. There was a minimal decrease of less than 10% in the number of neurons. In
Fig 7b, we studied the effect of having both the ApoE4 allele as well as a two-fold increase in
vessel stiffness. This combination led to a significant increase in Aβ deposition within the brain
parenchyma of both forms (Aβ42> Aβ40). Beta amyloid deposition within the cerebral vessels
was decreased compared to normal aging, however, this decrease was not as severe as that seen
in with only increased stiffness. This suggests that ApoE has more of an effect on the deposition
of Aβ within the cerebral vessels rather than the brain parenchyma. There was significant
Modeling Alzheimer's Disease Pathogenesis
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neuronal loss in this simulation, with no changes noted in the microglia or endothelial cell
number. Fig 7c shows the effect of increased vessel stiffness with bradycardia. The results of
this simulation were nearly identical to those of increased stiffness alone, suggesting that the
effect of bradycardia when there is underlying cardiovascular dysfunction (increased vessel
stiffness) is minimal. A summary of the results for each simulation are included in Table 3.
Fig 3. Simulation demonstrating effects of normal aging on Aβ levels within the brain parenchyma and local cerebral vessels. (A) Deposition of
Aβ40 occurred much more rapidly than that of Aβ42 with approximately 6 times the amount of Aβ40 deposited within cerebral vessels. This ratio agrees with
what has been observed experimentally. The rate of Aβ increase started to decrease over the simulation as the number of neurons declined with aging and
from elevations in the Aβ concentration. (B) The number of endothelial cells (blue) decreased slowly as they entered senescence. Microglia (green)
decreased about 80% from their initial values, correlating with conversion to dystrophy. Neurons (red) also decreased secondary to natural loss as well as
loss from elevated Aβ levels. (C) The total number of LRP-1 receptors decreased to approximately 60% of the initial value in accordance with the loss of brain
endothelial cells.
doi:10.1371/journal.pone.0139574.g003
Modeling Alzheimer's Disease Pathogenesis
PLOS ONE | DOI:10.1371/journal.pone.0139574 October 8, 2015 10 / 20
A sensitivity analysis was performed on the parameters that were estimated instead of
derived from the literature (Fig 8). Changes in the initial concentration of beta amyloid within
the perivascular space (C2/C5) were studied from a range of ½ normal to 2 times normal with
no changes in the simulation results observed, suggesting that the model is stable for changes
in this value. Analysis on the stability of the k4 rate constant (the increase in beta amyloid
Fig 4. Effect of heart rate on Aβ clearance and deposition. (A, B) Decreasing the heart rate by only 10 beats per minute (60 to 50) led to nearly a 20%
increase in the Aβ deposition in the brain parenchyma and a 5% increase in the cerebral vasculature. (C, D) Increasing heart rate by 30 beats per minute (60
to 90) led to the converse, with Aβ deposition levels in brain parenchyma decreasing about 30% and in the cerebral vessels decreasing about 10%.
doi:10.1371/journal.pone.0139574.g004
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Fig 5. Effect of vessel stiffness on Aβ clearance and deposition. (A) Increasing the stiffness slowly by a factor of 2 during aging led to a significant
increase in the amount of Aβ deposited within the brain parenchyma, with a decrease in the amount reaching and thus depositing in cerebral vessels. (B) The
high Aβ levels in the brain parenchyma led to accelerated neuronal loss with no change observed in microglia or brain endothelial cell number.
doi:10.1371/journal.pone.0139574.g005
Fig 6. Effect of ApoE allele on Aβ clearance and deposition. (A) Levels of Aβ40 deposition in cerebral vessels increased nearly two-fold with only a 67%
increase in Aβ42 deposition there. No changes from baseline simulations were noted in Aβ levels in the brain parenchyma. (B) No changes in cell number
were observed compared to baseline values for aging.
doi:10.1371/journal.pone.0139574.g006
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Fig 7. Combination effect of bradycardia, ApoE4 allele and increased vessel stiffness. (A) Having both bradycardia and the ApoE4 allele led to
elevated levels of Aβ40 deposition in both the brain parenchyma and the cerebral vessels, with nearly a two-fold increase in Aβ40 in the cerebral vessels.
There was a small decrease in the number of neurons at the final simulation endpoint (<10%). (B) In the case where the simulated patient was supposed to
have cardiovascular disease (represented by increased vessel stiffness) and carry the ApoE4 allele, Aβ deposition was significantly elevated within the brain
parenchyma (100x and 1000x for Aβ40 and Aβ42, respectively). The decreased levels of Aβwithin the cerebrovasculature was not quite as significant as
with increased vessel stiffness alone, suggesting that the ApoE allele plays an important role in determining deposition and Aβ concentration within the space
Modeling Alzheimer's Disease Pathogenesis
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generation in response to stimuli such as elevated levels of Aβ) demonstrated a narrow range of
stability. Increasing k4 to 2 from 1.5 led to almost a 30% increase in Aβ levels in all compart-
ments modeled. Further increases in k4 (not shown) continued to show a similar trend.
Discussion
The mathematical model developed in this paper studies the role that clearance by the glym-
phatic system and LRP-1 at the blood-brain barrier plays in pathogenesis of AD. Altered
near cerebral vessels. The significantly elevated Aβ levels led to a decrease in the neuronal cell number secondary to increased neuronal death rate seen at
high Aβ levels. (C) The results of increased vessel stiffness in the presence of bradycardia led to results that were similar to those seen with increased vessel
stiffness alone.
doi:10.1371/journal.pone.0139574.g007
Table 3. Summary of simulation results.
Aβ in: Brain parenchyma Cerebral Vessel
Normal aging 5.929x109 6.8575x109
1.187x109 1.0685x109
Bradycardia (HR = 50) 1.20 1.05
1.19 1.07
Elevated HR (HR = 90) 68.5 90.7
69.2 85.1
Elevated vessel stiffness (2x) 144.92 9.04x10−6
1741.45 9.07x10−6
ApoE4 allele No change 1.96
No change 1.62
ApoE4 allele & bradycardia (HR = 50) 1.20 2.16
1.19 1.83
ApoE4 allele & increased vessel stiffness 144.92 2.9x10−5
1741.45 2.98x10−4
Bradycardia & increased vessel stiffness 144.92 9.04x10−6
1741.45 9.07x10−6
Increased beta amyloid generation (2x) 1.31 1.29
1.30 1.30
Under normal aging, Aβ40 within the brain parenchyma was found to be 5.929x10
9, while Aβ42 in the brain
parenchyma was 1.187x109. Within the cerebral vessel, Aβ40 was 6.8575x10
9 and Aβ42 was 1.068x10
9.
The ﬁnal endpoint value for each simulation was determined and then normalized to the corresponding
value obtained for the normal aging simulation to determine the normalized ratio. The normalized ratios for
Aβ40 are listed ﬁrst in each row, followed by the value for Aβ42. The results here show the dramatic
increase in beta amyloid within the brain parenchyma when vessel stiffness increases slowly during aging
to a maximum two-fold increase. There is also a corresponding decrease in the amount of Aβ at the
cerebral vessel. The only simulation condition that showed a decrease in Aβ was the elevated heart rate to
90 beats per minute. This simulation was trying to model the effect of daily exercise on Aβ clearance and
demonstrated the efﬁcacy of exercise in helping to increase Aβ clearance. The ﬁnal row describes the Aβ
normalized ratio when Aβ generation is increased two-fold as part of the sensitivity analysis. This
simulation demonstrated that increasing Aβ generation rate had an effect similar to bradycardia in the
overall levels of Aβ within the brain parenchyma, but led to further elevations in Aβ within the cerebral
vasculature with respect to the bradycardia and normal aging simulations. These results suggests that
increased Aβ generation alone is not responsible for the elevated levels of Aβ seen in the brains of patients
with AD, though the role of vessel stiffness may play a very important role.
doi:10.1371/journal.pone.0139574.t003
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clearance levels have been implicated as causal factors in the development of AD [60–64].
Results of the model for normal aging demonstrated a gradual increase in Aβ deposition in
both the brain parenchyma and the cerebral vessels which correlates well to experimental
results [5, 35, 49]. Monitoring neuron, microglia and brain endothelial cell numbers allowed us
to track the steady decline in functional cells of each type that occurs normally with aging. One
of the limitations of this model is that transport of Aβ by diffusion down its concentration gra-
dient from neurons to the BBB was not incorporated as little experimental data is available at
Fig 8. Sensitivity analysis of the model. (A)The sensitivity of the model to values that were estimated was studied to determine the range over which the
model produced stable simulation results. Changing the initial concentration of Aβ from½ x to 2x led to no changes in simulation result and demonstrating
stability of this rate constant. (B) Changing the amount that Aβ generation would increase in response to a stimulus (k4) showed that this parameter had a
relatively narrow range of stability.
doi:10.1371/journal.pone.0139574.g008
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this time. Given what is known of transport properties in the brain, diffusion has been theo-
rized to be an important contributor to movement of chemical species in the brain ISF when
species are traveling short distances in the grey matter (few-tens of microns), however, it is
believed that convective flow dominates in white matter tracts [26, 65]. Future experimental
work will help to better elucidate this mechanism and allow for more accurate modeling.
Cardiovascular risk factors such as the ApoE4 allele, prolonged hypertension leading to re-
modeling of vessels and hyperlipidemia have also been recognized as risk factors for AD. In
this model, we found that increasing the vessel stiffness by a factor of just 2 from baseline led to
a significant increase in the deposition of Aβ in the brain parenchyma most likely secondary to
decreased transfer of arterial pulsations and thus, decreased bulk ISF flow. These simulations
clearly demonstrated the importance that changes in vessel structure can have in the clearance
of Aβ from the brain and offer insight into the disease process, as well as a possible modifiable
risk factor. Further research looking at the effect of better blood pressure management and pre-
vention of vessel re-modeling and its effect on AD pathogenesis would provide the necessary
evidence to determine if this is a viable AD prevention strategy.
Increasing vessel stiffness in combination with having the ApoE4 allele led to a 10-fold
increase in Aβ within the cerebral vasculature compared to the value for increased stiffness
only. A similar trend for increased cerebrovasculature deposition of Aβ was seen in other simu-
lations where the ApoE4 allele was included, suggesting the importance that ApoE4 plays in
deposition of Aβ in the vasculature. Although ApoE4 is not a modifiable risk factor for AD,
this model suggests that being a carrier for it may increase ones risk of having cerebrovascula-
ture deposits of Aβ otherwise known as cerebral amyloid angiopathy (CAA). Further study is
still needed to better understand the role that ApoE may play in competitive inhibition of Aβ
transport at the blood-brain barrier and its possible role in CAA.
Studying the effect of elevated heart rate on Aβ clearance demonstrated that raising heart
rate (90 beats per minute) as can happen during exercise, is beneficial for removing Aβ from
the brain. Though this effect was modest, it still demonstrated the positive benefit that exercise
can have, especially for the elderly [66–68].
This model represents an attempt to study multi-level interactions between cells within the
brain, Aβ levels, LRP-1 levels and the ApoE allele. Future models should look at the interaction
between this system and the role that inflammation and cholesterol processing may play in AD
pathogenesis. Sleep is also known to be a major determinant of beta amyloid clearance via the
glymphatic system, however, experimental rate constants in humans on how shortened lengths
of sleep may affect clearance requires further investigation but would be an important parame-
ter to include in future models [69]. Also, as further in vivo research that accurately measures
parameters for diffusion and convection in the brain become available, including the role of the
aquaporin-4 receptor in the glymphatic clearance pathway, the model can be refined to include
these newer parameters to more accurately model the system and increase our understanding
of divergence of AD progression from normal aging [11, 70].
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